Archana Swami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Archana Swami has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Purva Kanvinde
Department of Paediatric Hematology-Oncology, Bai Jerbai Wadia Hospital for Children
2 shared publications - Sangeeta Mudaliar
Department of Paediatric Hematology-Oncology, Bai Jerbai Wadia Hospital for children, Mumbai, Maharashtra, India
2 shared publications Alexander R. Votruba
Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
1 shared publication- Bruce R. Zetter
Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, USA
1 shared publication - Eric M. Pridgen
Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, USA
1 shared publication - Jinjun Shi
Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by Medknow in Indian Journal of Cancer
- Vol. 60 (1) , 134-139
Early response to chemotherapy in children with Langerhans cell histiocytosis predicts long-term disease-free survival
Background: Langerhans cell histiocytosis (LCH) is a rare clonal malignancy of the monocyte-macrophage system. Patients with lesions in “risk organs” have significantly higher risk of mortality than patients with lesions limited to “non-risk” sites. The influence of early response to therapy on long-term survival in this heterogeneous multi-system disease was analyzed. Methods: During a 7-year period, we retrospectively analyzed the findings in 24 consecutive patients who required systemic chemotherapy for LCH [single system with multifocal bone involvement and multisystem involvement with or without risk organ (RO) involvement]. All patients were started on vinblastine and prednisolone. Progressive disease was treated with salvage protocols or targeted therapy. Positron emission tomography-computed tomography (PET-CT)/conventional CT based response assessment was performed at week 6 of chemotherapy, and if needed after week 12 of chemotherapy. Results: MFO bone, MS ROneg, and MS ROpos LCH was observed in 3, 4, and 17 patients, respectively. Age range of patients varied from 1 month–7 years (median = 18 months). The EFS and OS were 100% and 100% for MFO bone, 50% and 100%, respectively, for MS ROneg and 35% and 52%, respectively, for MS ROpos. OS was 93% and 100% for CR attained at 6 and 12 weeks respectively regardless of the risk status (P < 0.01). Conclusion: Rapid early response, that is, complete remission at 6 and 12 weeks was associated with significantly improved overall survival. In slow responders, early salvage with alternative regimens or targeted therapy may result in better outcomes.
- 1 January 2023
- Published by Medknow in Indian Journal of Cancer
- Vol. 60 (1) , 134-139
Open AccessEarly response to chemotherapy in children with Langerhans cell histiocytosis predicts long-term disease-free survival
Background: Langerhans cell histiocytosis (LCH) is a rare clonal malignancy of the monocyte-macrophage system. Patients with lesions in “risk organs” have significantly higher risk of mortality than patients with lesions limited to “non-risk” sites. The influence of early response to therapy on long-term survival in this heterogeneous multi-system disease was analyzed. Methods: During a 7-year period, we retrospectively analyzed the findings in 24 consecutive patients who required systemic chemotherapy for LCH [single system with multifocal bone involvement and multisystem involvement with or without risk organ (RO) involvement]. All patients were started on vinblastine and prednisolone. Progressive disease was treated with salvage protocols or targeted therapy. Positron emission tomography-computed tomography (PET-CT)/conventional CT based response assessment was performed at week 6 of chemotherapy, and if needed after week 12 of chemotherapy. Results: MFO bone, MS ROneg, and MS ROpos LCH was observed in 3, 4, and 17 patients, respectively. Age range of patients varied from 1 month–7 years (median = 18 months). The EFS and OS were 100% and 100% for MFO bone, 50% and 100%, respectively, for MS ROneg and 35% and 52%, respectively, for MS ROpos. OS was 93% and 100% for CR attained at 6 and 12 weeks respectively regardless of the risk status (P < 0.01). Conclusion: Rapid early response, that is, complete remission at 6 and 12 weeks was associated with significantly improved overall survival. In slow responders, early salvage with alternative regimens or targeted therapy may result in better outcomes.
- Open Access
- 10 September 2021
- Published by Springer Nature in Journal of Hematopathology
- Vol. 14 (4) , 321-323
An uncommon RBC membranopathy: two case reports
- 10 September 2021
- Published by Springer Nature in Journal of Hematopathology
- Vol. 14 (4) , 321-323
Open AccessAn uncommon RBC membranopathy: two case reports
- Open Access
- 1 July 2014
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 10 (5) , e897-e900
Hybrid lipid–polymer nanoparticles for sustained siRNA delivery and gene silencing
- 1 July 2014
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 10 (5) , e897-e900
Open AccessHybrid lipid–polymer nanoparticles for sustained siRNA delivery and gene silencing